By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Shire LLC et al. v. Sandoz Inc.
1:12-cv-00040; filed January 6, 2012 in the District Court of Colorado
• Plaintiffs: Shire LLC; Supernus Pharmaceuticals, Inc.; Shire Development Inc.; Shire International Licensing B.V.; Amy F.T. Arnsten; Pasko Rakic; Robert D. Hunt
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 5,854,290 ("Use of Guanfacine in the Treatment of Behavioral Disorders," issued December 19, 1998), 6,287,599 ("Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles," issued September 11, 2001), and 6,811,794 (same title, issued November 2, 2004) based on Sandoz's amendment of its ANDA (adding additional dosage forms) to manufacture a generic version of Shire's Intuniv® (guanfacine, used to treat attention-deficit hyperactivity disorder). View the complaint here.
Takeda Pharmaceutical Co. et al v. Mylan, Inc. et al.
2:12-cv-00026; filed January 6, 2012 in the Western District of Pennsylvania
• Plaintiffs: Takeda Pharmaceutical Co.; Takeda Pharmaceuticals North America, Inc.; Takeda Global Research and Development Center, Inc.; Watson Pharmaceuticals, Inc.; Andrx Labs, LLC
• Defendants: Mylan, Inc.; Mylan Pharmaceuticals, Inc.
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,099,859 ("Controlled Release Oral Tablet Having a Unitary Core," issued August 8, 2000), 6,495,162 (same title, issued December 17, 2002), 6,790,459 ("Methods for Treating Diabetes Via Administration of Controlled Release Metformin," issued September 14, 2004), 6,866,866 ("Controlled Release Metformin Compositions," issued March 15, 2005), 7,785,627 ("Pharmaceutical Formulation Containing a Biguanide and a Thiazolidinedione Derivative," issued August 31, 2010), 7,919,116 ("Controlled Release Metformin Composition," issued April 5, 2011), and 7,959,946 ("Pharmaceutical Formulation Containing a Biguanide and a Thiazolidinedione Derivative," issued June 14, 2011) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Takeda's ACTOplus met® XR (pioglitazone and metformin, used an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes). View the complaint here.
Comments